The effects of add-on therapy of DPP4 inhibitor, Vildagliptin, on glucose control and diabetic complication in type 2 diabetes mellitus treated with insulin administration

Trial Profile

The effects of add-on therapy of DPP4 inhibitor, Vildagliptin, on glucose control and diabetic complication in type 2 diabetes mellitus treated with insulin administration

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Vildagliptin (Primary) ; Insulin
  • Indications Diabetic nephropathies; Diabetic retinopathy; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 07 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 01 Apr 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top